We design, develop, and commercialize biologics
Forbius (Formation Biologics) is a clinical stage protein engineering company that designs, develops, and commercializes biotherapeutics for the treatment of cancer and fibrotic diseases. Forbius was founded in 2011 as a management-led spin out from YM BioSciences, prior to YM's acquisition by Gilead.
Forbius’ medicines are designed to radically transform patients’ lives. Our strength is utilizing our knowledge of biology and diverse protein engineering technologies to design superior inhibitors of validated biological pathways.
Targeting TGF-beta and EGFR Pathways in Fibrosis and Cancer
Our current focus is the development of agents targeting the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways. For both of these pathways, there is a significant body of evidence validating their role as drivers of multiple life-threatening conditions. However, in the case of the EGFR pathway, the majority of patients do not benefit from currently marketed EGFR inhibitors. In the case of the TGF-beta pathway, not a single agent targeting this pathway has yet been approved. By using multiple complimentary platform technologies, Forbius’ team overcame barriers that prevented development of highly-active therapeutics targeting these pathways.
By utilizing multiple complementary platform technologies, Forbius engineers proprietary, fit-for-purpose biotherapeutics positioned to
become the new standard of care. Our strength is designing highly active inhibitors of validated pathways that have a differentiated
mechanism of action.
- In Silico
Receptor ectodomain-based traps
Forbius uses receptor ectodomain-based trap technology to design selective and potent traps that neutralize ligands that are over-expressed in disease. We have a unique approach to designing traps that results in superior potency compared to traditional trap engineering approaches.
Forbius uses novel immunization and screening approaches to enable identification of unique monoclonal antibodies (mAbs) with desired activities.
Forbius utilizes antibody-drug conjugate (ADC) technology to enhance the activity of antibodies targeting internalizing cell surface proteins that are over-expressed in disease.
Forbius utilizes cutting-edge in silico protein modelling platforms to accelerate and optimize design of its biotherapeutics.
AVID100 is a highly potent anti-EGFR antibody-drug conjugate. This agent successfully completed Phase 1 testing and is now undergoing Phase 2a clinical trials in EGFR-overexpressing tumors.
AVID200 is designed to be a highly potent and isoform-selective TGF-β inhibitor. This agent is unique because it selectively neutralizes TGF-β1 and -β3 with pM potency, while at the same time being minimally active against TGF-β 2. Inhibiting the TGF-β1 and -β3 isoforms is advantageous because overexpression of these isoforms is closely associated with the progression of fibrosis and cancer. Conversely, blockade of TGF-β2 is undesirable because of the potential impact on normal cardiac function and dissemination of metastasis. We therefore believe that AVID200 is ideally positioned to be an effective and well-tolerated therapeutic in a variety of clinical settings. AVID200 is undergoing development for the treatment of fibrotic diseases and immune oncology.
Fibrosis, subcutaneous formulation
Led by Innovators
- Board of Directors
- Advisors & Collaborators
Paul Nadler M.D., FCP, FACP
Michael B. Sporn, M.D.
Ronald Hoffman, M.D.
Robert Lafyatis, M.D.
Working at Forbius
Forbius is a rapidly growing, science-driven company. We are pleased to hear from individuals with a track-record of achievement who are interested in joining our team. Click here to learn more about our corporate culture and open positions.